Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2006

01-08-2006 | Clinical trial

Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients

Authors: Marco Tampellini, Alfredo Berruti, Raffaella Bitossi, Gabriella Gorzegno, Irene Alabiso, Alberto Bottini, Antonio Farris, Michela Donadio, Maria Giuseppa Sarobba, Enrica Manzin, Antonio Durando, Enza Defabiani, Andrea De Matteis, Mara Ardine, Federico Castiglione, Saverio Danese, Elena Bertone, Oscar Alabiso, Marco Massobrio, Luigi Dogliotti

Published in: Breast Cancer Research and Treatment | Issue 3/2006

Login to get access
Metadata
Title
Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients
Authors
Marco Tampellini
Alfredo Berruti
Raffaella Bitossi
Gabriella Gorzegno
Irene Alabiso
Alberto Bottini
Antonio Farris
Michela Donadio
Maria Giuseppa Sarobba
Enrica Manzin
Antonio Durando
Enza Defabiani
Andrea De Matteis
Mara Ardine
Federico Castiglione
Saverio Danese
Elena Bertone
Oscar Alabiso
Marco Massobrio
Luigi Dogliotti
Publication date
01-08-2006
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2006
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-005-9155-y

Other articles of this Issue 3/2006

Breast Cancer Research and Treatment 3/2006 Go to the issue

Epidemiology

Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians

OriginalPaper

The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth

Epidemiology

Diabetes mellitus and breast cancer: a retrospective population-based cohort study

Erratum

High Prognostic Significance of Residual Disease After Neoadjuvant Chemotherapy: a Retrospective Study in 710 Patients with Operable Breast Cancer

OriginalPaper

Clinicopathologic factors associated with false negative FDG–PET in primary breast cancer

Preclinical study

Isolation and characterization of a breast progenitor epithelial cell line with robust DNA damage responses
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits